PD1CD28 嵌合分子在小鼠模型异种移植实验中增强 EGFRvⅢ 特异性 CAR-T 细胞

Over the years, CAR-T cell therapy has achieved remarkable success in treating hematological malignancies.

However, this efficacy has not been replicated in the context of glioblastoma (GBM). In this study, a PD1CD28 chimeric molecule was introduced into EGFRv -directed CAR-T cells, generating EGFRv -P2A-PD1CD28 CAR-T cells.

Notably, this modification significantly increased IL-2 secretion and enhanced antigen-dependent activation of CAR-T cells, especially when programmed cell death ligand 1 (PD-L1) was present in vitro.

In addition, the in vivo xenograft experiments revealed that the PD1CD28 chimeric molecule played a pivotal role in reducing recurrence rates, effectively controlling recurrent tumor volume, and ultimately prolonging the survival of mice. Collectively, these findings suggest that EGFRv -directed CAR-T cells co-expressing the PD1CD28 chimeric molecule have the potential to significantly enhance the treatment efficacy against GBM.